Greenfern Industries Limited (GFI) is about to commence the writing of clinical trial protocols for a low dose CBD medication that could set it on the pathway to become a pharmacist-only, over-the-counter product registered in Australia. In February 2021 the Australian Therapeutics Goods Administration (TGA) made it legal to purchase products containing low-dose (less that 150mg per day) of cannabidiol (CBD) over the counter.
